Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Alopecia areata patients have a higher risk of subclinical atherosclerosis, and carotid ultrasound can help assess their cardiovascular risk.

Certain gene variations may increase the risk and severity of alopecia areata.

Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

Alopecia Areata Incognita causes widespread hair thinning, and treatment with systemic corticosteroids and psychiatric support can lead to remission.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

The new clobetasol propionate foam is effective and safe for treating alopecia areata.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

Combining light therapy, acid, and microneedling improves hair regrowth in stubborn hair loss cases.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Alopecia areata in US adolescents leads to significant healthcare costs and usage.

The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.

More research is needed on alopecia areata treatments and its psychological effects.

Baricitinib is effective and safe for treating alopecia areata in Korea.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.

The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.

An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.

A comprehensive approach is needed to accurately assess alopecia areata severity and guide treatment decisions.

LC-OCT is a useful noninvasive tool for diagnosing and monitoring alopecia areata.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Hair loss can cause emotional and social issues, and various treatments, including medication, surgery, and psychological support, are needed.